At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti-Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium Dose Mometasone Furoate DPI and MDI Formulations in Adults and Adolescents With Persistent Allergic Asthma
In Brief
A Phase 2 clinical trial evaluating mometasone furoate/formoterol 100/10 mcg, mometasone furoate/formoterol 200/10 mcg, and 4 other interventions for Asthma and Airway Inflammation. Completed, enrolled 93 participants.
Detailed Summary
This is a 2-week double-blind, placebo-controlled, parallel group study comparing the anti-inflammatory effects of low, medium, and high dose mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) formulation and medium dose mometasone furoate (MF) dry powder inhaler (DPI) and MDI formulations in adults and adolescents with persistent allergic asthma.
Study Details
Timeline
Interventions
mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days
mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days
mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days
MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days
MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days
MF/F MDI placebo twice daily (BID) (2 inhalations)